Metraipolis › archive › dc_37deb61eae34
Lenalidomide-rituximab with high-dose methotrexate for treatment of patients with newly diagnosed primary cns lymphoma: a promising first-line approach — Europe PMC PMID:41037103
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41037103
- DOI
- 10.1007/s00277-[numero omesso]-7
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-10T04:52:40.222Z
- SHA-256 of the archived text
6b0ab4731e66a1c71c42bea69a6586b5c889e34b0f9d804ba0359d5ff550c16d- Stable URL of this page
https://metraipolis.com/documento/dc_37deb61eae34
How to cite
Lenalidomide-rituximab with high-dose methotrexate for treatment of patients with newly diagnosed primary cns lymphoma: a promising first-line approach — Europe PMC PMID:41037103 — Europe PMC (en), https://europepmc.org/article/MED/41037103 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_37deb61eae34 (Metraipolis archive dc_37deb61eae34, sha256 6b0ab4731e66a1c71c42bea69a6586b5c889e34b0f9d804ba0359d5ff550c16d)
BibTeX
@misc{dc37deb61eae34,
title = {Lenalidomide-rituximab with high-dose methotrexate for treatment of patients with newly diagnosed primary cns lymphoma: a promising first-line approach — Europe PMC PMID:41037103},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41037103},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_37deb61eae34; sha256 6b0ab4731e66a1c71c42bea69a6586b5c889e34b0f9d804ba0359d5ff550c16d},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41037103. Agents can read the archived copy with the MCP tool read_document.